🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

RAIRDs are a range of conditions in which the body’s immune system damages its own tissues. These conditions include vasculitis, lupus, scleroderma, and Sjögren’s syndrome. RAIRDs can be life-threatening and significantly life-altering. #RAIRDaware #AutoimmuneDiseases #Health

I wrote a book..! Out now 👇

We’re raising awareness of the devastating condition HLH with our new consensus pathway & guidance, out now EVERYONE needs to see this ▶️bit.ly/4dH69uq Thanks to BSR & Histio UK for collaboration 1/2 Peter Lanyon Lesley Kay also on bluesky 💙 Rachel Tattersall Jessica Manson

Africa has a shortage of rheumatology expertise EULAR and RheumAFLAR support rheumatology training in #Africa by providing free access to high quality online rheumatology courses ➡️Apply below 💠Deadline 15 Sept 2024

Management of #Behcets The 2024 British Society for #Rheumatology & Dermatology ‘living guideline for managing people with Behcets’. Great Job! #MedTwitter

Highlighting inequities across MSK pathways - Supporting People With Musculoskeletal Conditions From Underserved Communities in the United Kingdom to Engage With Physical Activity: A Realist Synthesis and Q-Methodology Study doi.org/10.1123/jpah.2…

We're excited to be starting new research with NHS Bristol, N Somerset & S Gloucestershire ICB University of Bristol St George's, Epsom and St Helier to evaluate getUBetter, a self-management app. Part of a £7.8m investment by National Institute for Health and Care Research: nihr.ac.uk/news/nihr-and-… Congratulations to project lead Dr Alice Berry! Details: blogs.uwe.ac.uk/research-busin…

Many thanks Jim - this debate will be a brilliant opportunity to raise awareness of the need for improved care and treatment for RAIRDs Lupus UK SRUK | Scleroderma & Raynaud's UK Vasculitis - In memory of John Mills MBE 💙💚 ZoiAn Sue Farrington Sjögren's UK

A brilliant opportunity to learn and then share awareness of rare rheumatic diseases. Thank you for the opportunity to make people with RAIRDs more visible and drive the improvement of care RAIRDA Luke Pollard MP UK Parliament #vasculitis #rarediseases

😃Yes! This month's theme is adherence! 💎Adherence is one of the cornerstones of🔝 #lupus management, which requires a comprehensive & multifaceted approach to address the diverse aspects of the disease. 💪A significant part of the journey to #KickLupus lies within our grasp

One small step towards the right direction. Thank you!

📢 Join us for our Monthly Town Hall featuring the new PRISMA-COSMIN Guideline for reporting systematic reviews of Outcome Measurement Instruments (OMIs)! 🗓️ Dec 17, 2024, 8 AM EST 🔹 With experts Ellen Elsman & Martin Offringa. Review the guideline & video:

Transition care for rare connective tissue diseases in Europe 🔹67 responses from 59 centres, 20 countries 🔹Only 40% have a standardised policy 🔹29% transition based on age alone 🔹Key barriers: lack of guidelines and provider training ERN ReCONNET 🇪🇺 academic.oup.com/rheumap/articl…

Clinical trial diversity is not optional—it’s critical. As Dr. Gail Kerr, AWIR’s Director of Clinical Research, emphasizes: “Diversity in clinical trials is essential to understanding how various treatment approaches work in patients from different gene pools, backgrounds, and

Come join us for #IVW2026 in Australia, and in the vibrant city of Melbourne! February offers perfect summer weather - ideal for beach trips and exploring the city’s famous laneways. Join the Mailing List (vasculitis-melbourne2026.com) to keep up to date!

Excited to be the new Editor-in-Chief of Rheumatology Advances in Practice Rheumatology & Rheumatology Advances in Practice Honoured to follow in the footsteps of Prof Richard Watts and Dr Ai Lyn Tan The best way to predict the future is to create it. Join our vibrant community BSR doi.org/10.1093/rap/rk…

March is #AutoimmuneAwarenessMonth, a time to shine a light on #vasculitis & other autoimmune diseases Share this post to spread awareness of symptoms for vasculitis, a rare #rheumatic autoimmune disease with over 18 different types, each type extremely rare in its own right!

Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network pubmed.ncbi.nlm.nih.gov/40124776

Important publication on Treatment of Giant Cell Arteritis (GCA). "In patients with GCA, upadacitinib at a dose of 15 mg with a 26-week GCs taper showed efficacy superior to that of PBO with a 52-week GC taper. nejm.org/doi/pdf/10.105…

Avacopan Versus Prednisone Taper in Patients With ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial Sponsored by Amgen buff.ly/kIHOgfh